HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Aloe Supplement Makes Drug Claims, Touts HHS 'Certificate' Of Approval

This article was originally published in The Rose Sheet

Executive Summary

The FDA ORA Chicago District's lengthy inspection at a Illinois firm in May, June and July 2015 and a review of its website found drug claims including "helps control diabetes."

You may also be interested in...



FDA Salmonella Finding Triggers Recall Of Nopalina Flax Seed Fiber Products

Waukegan, IL-based Salud Natural Entrepreneur, Inc. is recalling lots of Nopalina Flax Seed Fiber powder and capsules after FDA tested an ingredient used in their manufacture and identified three types of Salmonella bacteria. The agency issued a warning letter to the firm in April 2016 for violations including GMP failures.

Aloe Farms' Claims, GMP Practices Rub FDA The Wrong Way

The firm's violative label claims include Aloe Vera Gel "cures everything" and its branding mistakes include failing to list all ingredients for its Aloe Capsules and Original Whole Leaf Aloe Vera Capsules.

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS108555

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel